StockData

Arcturus Therapeutics vs Capricor Therapeutics

ARCT and CAPR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ARCT and CAPR compare

Capricor Therapeutics is the larger company, worth 2.3 times as much as Arcturus Therapeutics ($554M against $238M).

Arcturus Therapeutics scores higher on the StockData Score (9 against 5 for Capricor Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricARCTCAPR
Size and price
Market cap$238M$554M
Share price$8.36$9.53
Change, 1 year2.8%62.4%
Change, 5 years−77.1%187%
Beta (5Y)2.161.18
Employees111231
StockData Score
Total score9 (better)5
Valuation score2 (better)0
Growth score00
Performance score2 (better)0
Health score55
Dividend score00
Valuation
P/S7.8×–
P/B1.4× (better)2.6×
FCF yield−26.3%−23.9% (better)
Fair value$8.63–
Margin of safety3.1%–
Growth
Revenue growth (TTM)−68.7%–
Revenue growth, 5Y average53.8%–
Profitability
Operating margin−311%–
Net margin−286%–
FCF margin−205%–
Return on equity−44.4% (better)−100%
Return on invested capital−534%–
Financial health
Debt / equity0.000.00
Current ratio6.686.77 (better)
Altman Z-score−1.080.06 (better)
Piotroski F-score23 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions87.9%67.6%
Held by insiders8.1%1.6%
Insider net buying, 12 months–−$8.4M
Short interest, % of float20.7%32.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.